A Phase 2, Open-Label, Single-Arm Study of Cabozantinib in Japanese Patients With Advanced Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Jan 2019
At a glance
- Drugs Cabozantinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Takeda
- 27 Jul 2018 Planned primary completion date changed from 30 Apr 2019 to 22 Aug 2020.
- 27 Jul 2018 Planned End Date changed from 31 Aug 2021 to 22 Aug 2020.
- 27 Jul 2018 Status changed from recruiting to active, no longer recruiting.